Effects of Remimazolam on outcomes after bladder cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of remimazolam, a new benzodiazepine, on postoperative outcomes in patients undergoing transurethral resection of bladder tumors for non-muscle-invasive bladder cancer. The research focuses on how remimazolam affects the incidence of emergence delirium and recurrence-free survival compared to traditional anesthetics like propofol. By examining these outcomes, the study aims to provide insights into the potential benefits of using remimazolam in surgical settings for bladder cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥50 years and \<90 years;
2. Preoperative diagnosis is non-muscle-invasive bladder cancer(Ta-T1);
3. Scheduled to undergo transurethral resection of bladder tumor;
4. Agree to participate, and provide written informed consent.

Exclusion Criteria:

1. Refuse to participate;
2. Emergent surgery;
3. Combined with other malignant tumors;
4. Use of benzodiazepines for 1 week within the last month before surgery;
5. Preoperative history of schizophrenia, epilepsy, parkinsonism or myasthenia gravis;
6. Inability to communicate in the preoperative period due to coma, profound dementia, language barrier, or end-stage disease;
7. Critical illness (preoperative American Society of Anesthesiologists physical status classification ≥IV), severe hepatic dysfunction (Child-Pugh class C), or severe renal dysfunction (undergoing dialysis before surgery);
8. The purpose of surgery is to make a diagnosis or preoperative judgement is that tumor cannot be completely removed.

Where it's running

• Beijing Tsinghua Chang Gung Hospital
  Beijing, Beijing Municipality, China Recruiting
• The Sixth Medical Center of PLA General Hospital
  Beijing, Beijing Municipality, China Recruiting
• Peking University First Hospital
  Beijin, Bejing, China Recruiting
• Guizhou Provincial People's Hospital
  Guiyang, Guizhou, China Recruiting
• Jiangsu Provincial People's Hospital
  Nanjing, Jiangsu, China Recruiting
• Shanghai 10th People's Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Wang Dong-Xin, MD, PhD — Peking University First Hospital
• Study coordinator: Wang Dong-Xin, MD, PhD
• Email: wangdongxin@hotmail.com
• Phone: 86 10 83572784

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

• Personalized 3D Tumoroids from Your Tumor to Test Treatments

  Researchers are using patient tumor tissue and blood to grow personalized 3D, vascularized tumoroids with autologous immune cells to help tailor treatments for kidney, bladder, and prostate cancers.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07820566

• Can citicoline help prevent cognitive decline after delirium in older adults with hip fracture?

  This study tests whether taking citicoline for 6 months after discharge helps prevent cognitive decline in adults 65 and older who had delirium during hospitalization for hip fracture.

  Recruiting Phase 2 University of Milano Bicocca · Monza, Monza E Brianza · NCT07804498

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.